Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-Related outpatient illness among adults, October 2021-February 2022.

Sara S. Kim,Jessie R. Chung,H. Keipp Talbot,Carlos G. Grijalva,Karen J. Wernli,Erika Kiniry,Emily T. Martin,Arnold S. Monto,Edward A. Belongia,Huong Q. McLean,Manjusha Gaglani,Mufaddal Mamawala,Mary Patricia Nowalk,Krissy Moehling Geffel,Sara Y. Tartof,Ana Florea,Justin S. Lee,Mark W. Tenforde,Manish M. Patel,Brendan Flannery,Meghan L. Bentz, Alex Burgin, Mark Burroughs, Morgan L. Davis,Dakota Howard,Kristine Lacek, Joseph C. Madden,Sarah Nobles, Jasmine Padilla,Mili Sheth

Influenza and other respiratory viruses（2022）

引用 10|浏览6

暂无评分

摘要

In this adult population, three mRNA COVID-19 vaccine doses provided substantial protection against symptomatic illness in outpatient settings when the Omicron variant became the predominant cause of COVID-19 in the United States. These findings support the recommendation for a third mRNA COVID-19 vaccine dose.

查看译文

关键词

COVID‐19,outpatient,vaccine effectiveness

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要